Literature DB >> 23858338

Old World cutaneous leishmaniasis: diagnosis and treatment.

Abderrahmen Masmoudi1, Wala Hariz, Slaheddine Marrekchi, Mariem Amouri, Hamida Turki.   

Abstract

Cutaneous leishmaniasis is a major world health problem. Diagnosis is suspected on evocative clinical presentation in patients living in or coming from endemic areas. Several methods have been used. The smear is a simple investigation used in endemic regions. The culture enables to identify the specimen. PCR has a high sensitivity. Montenegro's reaction is used in the epidemiological study. Pentavalent antimony derivatives remain the mainstay of systemic treatment. Their efficiency is well established. Their toxicity should be researched. Other treatments can be utilized, such as miltefosine. Local therapy is used in uncomplicated lesions. Injections of the pentavalent antimony derivate, cryotherapy and paromomycin ointmentsis are important options and should be used more frequently in Old World leishmaniasis.

Entities:  

Keywords:  Glucantime; PCR; antimony; cutaneous leishmaniasis; diagnosis; leishmania; mucosal leishmaniasis; treatment

Year:  2013        PMID: 23858338      PMCID: PMC3710675          DOI: 10.3315/jdcr.2013.1135

Source DB:  PubMed          Journal:  J Dermatol Case Rep        ISSN: 1898-7249


  67 in total

1.  Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.

Authors:  G Faghihi; R Tavakoli-kia
Journal:  Clin Exp Dermatol       Date:  2003-01       Impact factor: 3.470

2.  Comparison of PCR assays for diagnosis of cutaneous leishmaniasis.

Authors:  Esther Bensoussan; Abedelmajeed Nasereddin; Flory Jonas; Lionel F Schnur; Charles L Jaffe
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

3.  Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial.

Authors:  R Reithinger; M Mohsen; M Wahid; M Bismullah; R J Quinnell; C R Davies; J Kolaczinski; J R David
Journal:  Clin Infect Dis       Date:  2005-03-16       Impact factor: 9.079

4.  Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA4 antibody.

Authors:  F P Heinzel; R A Maier
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

5.  Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam.

Authors:  Esther J S K Lai A Fat; Martinus A Vrede; Ramon M Soetosenojo; Rudy F M Lai A Fat
Journal:  Int J Dermatol       Date:  2002-11       Impact factor: 2.736

6.  Enzyme immunoassay using Leishmania (Viannia) braziliensis antigens for laboratorial diagnosis of American cutaneous leishmaniasis.

Authors:  Camila de Pádua Vidigal; Viviane Mathias Marcussi; Lilian Mathias Marcussi; Jane Martha Graton Mikcha; Sandra Mara Alessi Aristides Arraes; Maria Valdrinez Campana Lonardoni; Thaís Gomes Verzignassi Silveira
Journal:  Acta Trop       Date:  2008-05-08       Impact factor: 3.112

Review 7.  Treatment of cutaneous leishmaniasis among travellers.

Authors:  J Blum; P Desjeux; E Schwartz; B Beck; C Hatz
Journal:  J Antimicrob Chemother       Date:  2004-01-16       Impact factor: 5.790

8.  Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.

Authors:  Wen-Wei Zhang; Greg Matlashewski
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

9.  Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice.

Authors:  F Janaina Soares Rocha; Ulrike Schleicher; Jochen Mattner; Gottfried Alber; Christian Bogdan
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

10.  Doxycycline for the treatment of cutaneous leishmaniasis.

Authors:  A Masmoudi; A Dammak; H Chaaben; N Maalej; F Akrout; H Turki
Journal:  Dermatol Online J       Date:  2008-08-15
View more
  23 in total

Review 1.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-11-17

2.  Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis.

Authors:  Yavuz Yesilova; Hacer Altın Surucu; Nurittin Ardic; Mustafa Aksoy; Abdullah Yesilova; Steve Oghumu; Abhay R Satoskar
Journal:  J Dermatolog Treat       Date:  2015-06-24       Impact factor: 3.359

3.  Leishmania-Derived Trimannose Modulates the Inflammatory Response To Significantly Reduce Leishmania major-Induced Lesions.

Authors:  Tara L Grinnage-Pulley; Daniel E K Kabotso; Chelsea L Rintelmann; Rajarshi Roychoudhury; Robert G Schaut; Angela J Toepp; Katherine N Gibson-Corley; Molly Parrish; Nicola L B Pohl; Christine A Petersen
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

Review 4.  Species typing in dermal leishmaniasis.

Authors:  Gert Van der Auwera; Jean-Claude Dujardin
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

5.  In Vitro and In Vivo Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors.

Authors:  Felipe Rodriguez; Sarah F John; Eva Iniguez; Sebastian Montalvo; Karina Michael; Lyndsey White; Dong Liang; Omonike A Olaleye; Rosa A Maldonado
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 6.  Exclusive Primary Lesion of Oral Leishmaniasis with Immunohistochemical Diagnosis.

Authors:  Tatiana Fernandes Araujo Almeida; Esmeralda Maria da Silveira; Cássio Roberto Rocha Dos Santos; Jorge Esquiche León; Ana Terezinha Marques Mesquita
Journal:  Head Neck Pathol       Date:  2016-06-03

7.  Depot Subcutaneous Injection with Chalcone CH8-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres as a Single-Dose Treatment of Cutaneous Leishmaniasis.

Authors:  Ariane de Jesus Sousa-Batista; Wallace Pacienza-Lima; Natalia Arruda-Costa; Camila Alves Bandeira Falcão; Maria Ines Ré; Bartira Rossi-Bergmann
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 8.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-12-01

9.  Development and Characterization of PLGA Nanoparticles Containing 17-DMAG, an Hsp90 Inhibitor.

Authors:  Kercia P Cruz; Beatriz F C Patricio; Vinícius C Pires; Marina F Amorim; Alan G S F Pinho; Helenita C Quadros; Diana A S Dantas; Marcelo H C Chaves; Fabio R Formiga; Helvécio V A Rocha; Patrícia S T Veras
Journal:  Front Chem       Date:  2021-05-13       Impact factor: 5.221

10.  Leishmaniases diagnosis: an update on the use of immunological and molecular tools.

Authors:  Milena de Paiva-Cavalcanti; Rayana Carla Silva de Morais; Rômulo Pessoa-E-Silva; Lays Adrianne Mendonça Trajano-Silva; Suênia da Cunha Gonçalves-de-Albuquerque; Diego de Hollanda Cavalcanti Tavares; Maria Carolina Accioly Brelaz-de-Castro; Rafael de Freitas E Silva; Valéria Rêgo Alves Pereira
Journal:  Cell Biosci       Date:  2015-06-17       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.